The website's “male only” label concerns the intended use of PSA testing, rather than a preparation step. Clinical relevance depends on the presence of a prostate and the individual's history.
PSA should not be used as routine screening in younger people without a clinical indication. It has potential benefits and limitations, including false-positive results and the possibility of finding a cancer that would not have caused harm. Testing requires an informed discussion.
The published guidance generally considers testing from age 50 for average-risk men, with earlier discussion from age 45 where risk is increased. Relevant factors include a significant family history of prostate cancer, Black ethnicity and inherited risk such as a BRCA2 mutation.
In men under 40, PSA should generally be reserved for a specific clinical indication or specialist recommendation. There is no absolute minimum age where a genuine indication exists, but routine testing of asymptomatic adolescents or young adults is inappropriate. The reason for testing should be documented.